1 results match your criteria: "RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN[Affiliation]"
An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.
EMBO Mol Med
February 2015
Disease Glycomics Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan
Article Synopsis
- BACE1 is a key enzyme involved in the production of amyloid-β (Aβ) peptide and is targeted for Alzheimer's disease treatment, but inhibiting it could cause side effects.
- Research shows that BACE1 has a specific sugar modification called bisecting GlcNAc, which is higher in Alzheimer's patients.
- Mice without the enzyme needed for this sugar modification show reduced Aβ production and improved cognitive functions, indicating that targeting the enzyme GnT-III could be a potential strategy for Alzheimer's therapies.